University Hospital Basel, Division of Gastroenterology and Hepatology
Basel, 4031, Switzerland
NCT Number: NCT02020395
The objective of this study is to examine ghrelin, amylin, glucagon and glucagon-like peptide (GLP)-1 responses to a test meal in lean and obese individuals.
Looking for future studies?
Notify Me11 year–16 year
All sexes
Interventional
Phase 1
Basel, 4031, Switzerland
The primary hypothesis is that obese adolescents have a disturbed balance of hormones associated with appetite regulation with less suppression of ghrelin and attenuated stimulation of GLP-1 secretion in response to meal intake compared to lean normal weight controls. A second aim of the study was to test which gastrointestinal peptides are most associated with insulin resistance.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
Time frame: 2 hours blood sampling
Relation of GLP-1 release to insulin secretion in normal weight and obese adolescents
Time frame: 2 hours blood sampling
Dynamics of gastrointestinal peptide secretion including Tmax and Cmax
University Hospital, Basel, Switzerland
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716579
Brain Diseases, Brain Neoplasms
Ljubljana, Slovenia
View Trial DetailsNCT05171855
Adult Growth Hormone Deficiency, Bone Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04701203
Endocrine System Diseases, Hypoparathyroidism
San Francisco, California, United States
View Trial DetailsNCT02781727
Bone Diseases, Bone Diseases, Developmental
Birmingham, Alabama, United States
View Trial Details